Literature DB >> 30937406

Corrigendum to "Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy" [Heliyon 4 (12) (December 2018) e01039].

Xiaosheng Wu1, Yanli Li2, Xin Liu2, Chunhua Chen3, Susan M Harrington2, Siyu Cao2, Tiancheng Xie2, Tu Pham4, Aaron S Mansfield5, Yiyi Yan5, Eugene D Kwon2,4, Liewei Wang6, Kun Ling3, Haidong Dong2,4.   

Abstract

[This corrects the article DOI: 10.1016/j.heliyon.2018.e01039.].

Entities:  

Year:  2019        PMID： 30937406      PMCID： PMC6426698          DOI： 10.1016/j.heliyon.2019.e01309

Source DB:  PubMed          Journal:  Heliyon        ISSN： 2405-8440


In the original published version of this article, Amanda Orzechowski was incorrectly listed as an author. This person has requested that they be removed as an author. Both the HTML and PDF versions of the article have been updated to correct the error.
  4 in total

1.  MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation.

Authors:  Narges Dastmalchi; Reza Safaralizadeh; Mohammad Ali Hosseinpourfeizi; Behzad Baradaran; Seyed Mahdi Banan Khojasteh
Journal:  Mol Biol Rep       Date:  2021-02-08       Impact factor: 2.316

2.  Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy.

Authors:  Yundi Chen; Lixue Wang; Mingfeng Zheng; Chuandong Zhu; Guosheng Wang; Yiqiu Xia; Ethan J Blumenthal; Wenjun Mao; Yuan Wan
Journal:  Bioact Mater       Date:  2021-07-21

3.  Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China.

Authors:  Tu Hu; Wei Sun; Yu Xu; Xinglong Qu; Yongjia Jin; Zhiguo Luo; Yong Chen
Journal:  Ann Transl Med       Date:  2021-11

4.  Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.

Authors:  Jesus Vera Aguilera; Jonas Paludo; Robert R McWilliams; Henan Zhang; Ying Li; Anagha B Kumar; Jarrett Failing; Lisa A Kottschade; Matthew S Block; Svetomir N Markovic; Haidong Dong; Roxana S Dronca; Yiyi Yan
Journal:  Melanoma Res       Date:  2020-08       Impact factor: 3.199
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.